KRAS and cancer: For example, sequencing at the initiation of treatment may fail to detect cancer cells harboring mutations that confer resistance to chemotherapeutics, such as mutations in KRAS. Over the course of treatment, selective pressure results in the expansion and proliferation of drug-resistant cells5.